|
Q4 FY2025
As of Dec 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
|
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | ||||||||
| Cash, cash equivalents, and restricted cash | ||||||||
| Accounts receivable, net of allowance for Current Expected Credit Loss ("CECL") - trade receivable of $0 and $134,960, respectively | ||||||||
| Prepayments | ||||||||
| Other receivables | ||||||||
| Total Current Assets | ||||||||
| Property and equipment, net | ||||||||
| Non-Current Assets | ||||||||
| Intangible asset | ||||||||
| VAT credit | ||||||||
| Total Other Assets | ||||||||
| Total Assets | ||||||||
| Liabilities and Equity | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable and accrued liabilities | ||||||||
| Due to related party | ||||||||
| Deferred income | ||||||||
| Series A warrants liabilities | ||||||||
| Total Current Liabilities | ||||||||
| Total Liabilities | ||||||||
| Shareholders' Equity: | ||||||||
| Ordinary shares: 285,714,286 shares authorized, par value: $0.875 per share, 18,884 and 17,165 Class A shares issued and outstanding as of December 31, 2025 and 2024, respectively; 11,658 and 11,658 Class B shares issued and outstanding as of December 31, 2025 and 2024, respectively | ||||||||
| Additional paid in capital | ||||||||
| Statutory reserve | ||||||||
| Accumulated deficit | ||||||||
| Accumulated other comprehensive income (loss) | ||||||||
| Total Shareholders' Equity | ||||||||
| Total Equity | ||||||||
| Total Liabilities and Shareholders' Equity | ||||||||
Loading...
